< back to search

Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5

Huang, Feng   •   Sun, Fei   •   Wan, Wei-Guo   •   Wu, Li-Jun   •   Dong, Ling-Li   •   Zhang, Xiao   •   Kim, Tae-Hwan   •   Sengupta, Raj   •   Šenolt, Ladislav   •   Wang, Yi   •   Qiu, Hao-Min   •   Porter, Brian   •   Haemmerle, Sibylle

published in: Chinese Medical Journal



endpoint

It's better to choose SEC.
SEC has (optional: compared with placebo) proved to be better.


basics

diagnosis:
ankylosing spondylitis
ankylosing spondylitis
ankylosing spondylitis
ankylosing spondylitis

localization:
not specified

method:
conservative therapy → injection
conservative therapy → injection therapy
conservative therapy → injection therapy
conservative therapy → injection
conservative therapy → injection therapy
conservative therapy → injection
conservative therapy → injection therapy
conservative therapy → injection

publication details

10.1097/CM9.0000000000001099
pubmed
2020
Journal Article
randomized controlled trial
yes
prospective
1+

▼
▲